Review Article

A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma

Figure 5

Expression of CXCL14/BRAK protein in HNSCC cells suppresses growth of the cells in vivo. (a) Tumor size of xenografted Tet-on BRAK HSC-2 cells. The mice were subcutaneously injected with 107 Tet-on BRAK HSC-2 cells, and the animals were provided 5% sucrose-containing water (Group I). Other mice were given sucrose solution containing 2 mg/mL doxycycline starting at 13 days (black arrow) after implantation of the tumor cells (Group II). A third group of mice were implanted with Tet-on BRAK HSC-2 cells that had been precultured in the presence of 0.1 μg/mL of doxycycline for 7 days (Group III). These mice were provided doxycycline-supplemented water 7 days before (white arrow) implantation of the tumor cells. ; ; between group I and II or III. * between Group II and III and ** between day 3 and day 6 of Group III. (b) Expression levels of CXCL14/BRAK proteins in transplanted tumor cells in vivo 35 days after transplantation, as determined by western blotting. *** , as indicated by the bracket. (Cited from [5]).
797619.fig.005a
(a)
797619.fig.005b
(b)